Analyst Ratings for [NAMS] NewAmsterdam Pharma Company N.V.

7/17/25	Initiated	Neutral	X
NAMS NewAmsterdam Pharma Goldman
$27
6/17/25	Initiated	Buy	X
NAMS NewAmsterdam Pharma Citigroup
$42
6/10/25	Initiated	Buy	X
NAMS NewAmsterdam Pharma Stifel
$44
6/4/25	Initiated	Overweight	X
NAMS NewAmsterdam Pharma Cantor Fitzgerald
$42
12/30/24	Initiated	Buy	X
NAMS NewAmsterdam Pharma H.C. Wainwright
$48
5/15/24	Initiated	Buy	X
NAMS NewAmsterdam Pharma TD Cowen
3/14/24	Initiated	Sector Outperform	X
NAMS NewAmsterdam Pharma Scotiabank
$35
1/18/24	Initiated	Buy	X
NAMS NewAmsterdam Pharma Guggenheim
$30
1/16/24	Initiated	Overweight	X
NAMS NewAmsterdam Pharma Piper Sandler
$37
10/30/23	Initiated	Outperform	X
NAMS NewAmsterdam Pharma RBC Capital Mkts
$25
1/6/23	Initiated	Outperform	X
NAMS NewAmsterdam Pharma Credit Suisse
$21
12/20/22	Initiated	Outperform	X
NAMS NewAmsterdam Pharma SVB Leerink
$19
12/19/22	Initiated	Buy	X
NAMS NewAmsterdam Pharma Jefferies
$24
12/19/22	Initiated	Outperform	X
NAMS NewAmsterdam Pharma William Blair

NAMS NewAmsterdam Pharma Company N.V.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events. It also develops obicetrapib for Alzheimer's disease. The company was founded in 2019 and is based in Naarden, the Netherlands.